Drug intelligence / Profile preview

SUNIPla-M

Development stage: Preclinical
Lead developer: PLABiologics
Modality: Stem Cell Therapies → Cell Therapies

Overview

SUNIPla-M is a placenta-derived mesenchymal stem cell (MSC) therapy being developed by PLABiologics for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Utilizing the company's proprietary MSC platform, the therapy is designed to leverage the regenerative and anti-inflammatory properties of placental stem cells to address liver inflammation and fibrosis associated with MASH. It is currently in the preclinical stage of development.

Brand names: SUNIPla-M
Other names: SUNIPla M

Beyond the preview

Go deeper on SUNIPla-M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SUNIPla-M.

Explore the full profile